De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
Immunotech Biopharm Inkomsten in het verleden
Verleden criteriumcontroles 0/6
Immunotech Biopharm's earnings have been declining at an average annual rate of -4.4%, while the Biotechs industry saw earnings growing at 31.7% annually.
Belangrijke informatie
-4.4%
Groei van de winst
0.7%
Groei van de winst per aandeel
| Biotechs Groei van de industrie | 11.0% |
| Inkomstengroei | n/a |
| Rendement op eigen vermogen | -395.0% |
| Nettomarge | n/a |
| Laatste winstupdate | 30 Jun 2024 |
Recente prestatie-updates uit het verleden
Opbrengsten en kosten
Hoe Immunotech Biopharm geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 30 Jun 24 | 0 | -309 | 51 | 194 |
| 31 Mar 24 | 0 | -322 | 52 | 186 |
| 31 Dec 23 | 0 | -335 | 53 | 177 |
| 30 Sep 23 | 0 | -315 | 65 | 164 |
| 30 Jun 23 | 0 | -296 | 76 | 150 |
| 31 Mar 23 | 0 | -307 | 87 | 163 |
| 31 Dec 22 | 0 | -318 | 98 | 176 |
| 30 Sep 22 | 0 | -333 | 103 | 205 |
| 30 Jun 22 | 0 | -347 | 108 | 233 |
| 31 Mar 22 | 0 | -351 | 106 | 237 |
| 31 Dec 21 | 0 | -354 | 104 | 241 |
| 30 Sep 21 | 0 | -383 | 94 | 266 |
| 30 Jun 21 | 0 | -412 | 84 | 291 |
| 31 Mar 21 | 0 | -426 | 76 | 285 |
| 31 Dec 20 | 0 | -439 | 69 | 279 |
| 30 Sep 20 | 0 | -336 | 56 | 206 |
| 30 Jun 20 | 0 | -232 | 43 | 134 |
| 31 Mar 20 | 0 | -171 | 36 | 98 |
| 31 Dec 19 | 0 | -109 | 28 | 62 |
Kwaliteitswinsten: 6978 is currently unprofitable.
Groeiende winstmarge: 6978 is currently unprofitable.
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: 6978 is unprofitable, and losses have increased over the past 5 years at a rate of 4.4% per year.
Versnelling van de groei: Unable to compare 6978's earnings growth over the past year to its 5-year average as it is currently unprofitable
Winst versus industrie: 6978 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (13.8%).
Rendement op eigen vermogen
Hoge ROE: 6978 has a negative Return on Equity (-395.02%), as it is currently unprofitable.